BioAdaptives (BioAdaptives) Interest Expense : $-0.17 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is BioAdaptives Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BioAdaptives's interest expense for the three months ended in Mar. 2024 was $ -0.06 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.17 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BioAdaptives's Operating Income for the three months ended in Mar. 2024 was $ -0.05 Mil. BioAdaptives's Interest Expense for the three months ended in Mar. 2024 was $ -0.06 Mil. BioAdaptives did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioAdaptives Interest Expense Historical Data

The historical data trend for BioAdaptives's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioAdaptives Interest Expense Chart

BioAdaptives Annual Data

Trend

Dec13

Dec14

Dec15

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.20

-0.23

-0.27

-0.29

-0.16

BioAdaptives Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.05	-0.05	-0.02	-0.04	-0.06

BioAdaptives Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.17 Mil.

BioAdaptives (OTCPK:BDPT) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioAdaptives's Interest Expense for the three months ended in Mar. 2024 was $-0.06 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-0.05 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.00 Mil.

BioAdaptives's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

BioAdaptives did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

BioAdaptives (BioAdaptives) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » BioAdaptives Inc (OTCPK:BDPT) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

2620 Regatta Drive, Suite 102, Las Vegas, NV, USA, 89128

Website

https://www.shopbioadaptives.com

BioAdaptives Inc is engaged in investigating, marketing and distributing natural plant- and algal-based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. Its products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. The human products are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness. Its product lines include PluriPain, PrimiLungs, SleepEZ, MindNMemory, Cell Rejuven and ProteinNMore.

Executives

Richard Chiang	other: Previous Officer and Director	460 BRANNAN STREET SUITE 78064, SAN FRANCISCO CA 94107
Barry Epling	director	2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Ferris Holding Inc.	10 percent owner	2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Gerald Epling	director, officer: Pres, CEO, Secretary, CFO	2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128